Stereotaxis, Inc. reiterated revenue guidance for the full year 2022. for the year, the company reiterates its expectation of revenue growth driven by continued commercial adoption of the Genesis RMN system and stable recurring revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.845 USD | +0.27% |
|
-0.54% | +5.71% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.71% | 151M | |
+6.28% | 213B | |
+9.56% | 184B | |
+28.20% | 153B | |
+34.10% | 113B | |
+0.80% | 63.66B | |
+18.78% | 53.53B | |
+0.13% | 49.11B | |
-4.30% | 38.73B | |
+1.63% | 36.26B |
- Stock Market
- Equities
- STXS Stock
- News Stereotaxis, Inc.
- Stereotaxis, Inc. Reiterates Revenue Guidance for the Full Year 2022